k141_20597_1	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	56.3	272	273	443	1.26e-109	323
k141_20597_1	SARG|gb|AAG04750.1|ARO:3004077|PmpM	21.7	189	273	477	4.86e-10	58.5
k141_20597_1	NCBI|AAG27731.1|1|1|norM-Burk|norM-Burk|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_NorM|AMR|efflux	23.4	184	273	462	3.92e-07	49.7
k141_341_1	NCBI|WP_204376222.1|1|1|tet(X1)|tet(X1)|hydroxylation|2|TETRACYCLINE|TETRACYCLINE|tetracycline-inactivating_monooxygenase_Tet(X1)|AMR|tetracycline	59.5	37	475	379	1.45e-07	52.4
k141_144169_1	CARD|gb|AAK37618.1|ARO:3005008|TxR	42.3	265	291	318	4.58e-66	208
k141_31161_1	SARG|gb|AAA85213.1|ARO:3002866|dfrD	44.4	160	168	162	1.29e-42	138
k141_31161_1	megares|MEG_2575|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRD_1	44.4	160	168	162	1.29e-42	138
k141_31161_1	megares|MEG_2574|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRD_1	44.4	160	168	166	1.45e-42	138
k141_31161_1	NCBI|WP_012655890.1|1|1|dfrE|dfrE|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrE|AMR|diaminopyrimidine	43.5	161	168	164	1.79e-40	133
k141_31161_1	megares|MEG_2576|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRD_1	44.4	151	168	154	2.68e-40	132
k141_31161_1	NCBI|WP_049581834.1|1|1|dfrA45|dfrA45|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA45|AMR|diaminopyrimidine	39.5	167	168	164	2.66e-37	125
k141_31161_1	megares|MEG_8062|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRA_1	41.9	167	168	195	3.18e-37	125
k141_31161_1	SARG|gb|WP_000949574.1|ARO:3005348|DfrA36	41.9	167	168	195	3.18e-37	125
k141_31161_1	SARG|gb|BAE15963.1|ARO:3002868|dfrG	39.8	161	168	165	3.88e-37	124
k141_31161_1	SARG|gb|WP_197749399.1|ARO:3005349|DfrA38	41.4	162	168	166	1.13e-36	123
k141_92973_4	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	51.9	54	89	461	1.13e-08	49.3
k141_92973_4	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	51.9	54	89	461	1.55e-08	48.9
k141_92973_4	ResF|poxtA-Ef_1_WP094899500.1_1	30.2	86	89	538	1.57e-08	48.9
k141_92973_4	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	30.2	86	89	543	1.57e-08	48.9
k141_92973_4	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	30.2	86	89	543	1.57e-08	48.9
k141_92973_4	SARG|gb|AVI44920.1|ARO:3004470|poxtA	32.2	87	89	542	1.91e-07	45.8
k141_92973_4	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	32.2	87	89	544	1.91e-07	45.8
k141_92973_4	SARG|gi|1046366091|gb|OCK16447.1|	38.0	71	89	498	3.55e-07	45.1
k141_92973_4	SARG|U82085.gene.p01	36.5	63	89	552	6.68e-07	44.3
k141_92973_4	SARG|gi|803568669|ref|WP_046077412.1|	40.8	71	89	648	6.75e-07	44.3
k141_31342_2	SARG|gi|742378414|ref|WP_038857601.1|	46.1	219	220	647	2.20e-57	191
k141_31342_2	SARG|gi|506220920|ref|WP_015740695.1|	45.7	219	220	647	1.61e-56	188
k141_31342_2	SARG|gi|504542119|ref|WP_014729221.1|	45.2	219	220	647	4.35e-56	187
k141_31342_2	SARG|gi|655997348|ref|WP_029038923.1|	45.2	219	220	647	4.35e-56	187
k141_31342_2	SARG|gi|426326769|emb|CCK10228.1|	45.2	219	220	648	4.40e-56	187
k141_31342_2	SARG|YP_001438541	45.2	219	220	647	6.05e-56	187
k141_31342_2	SARG|gi|938461734|ref|WP_054625806.1|	45.2	219	220	647	6.05e-56	187
k141_31342_2	SARG|gi|938460528|ref|WP_054624864.1|	45.2	219	220	647	6.05e-56	187
k141_31342_2	SARG|gi|1020141879|ref|WP_063264839.1|	45.2	219	220	647	6.05e-56	187
k141_31342_2	SARG|gi|490522515|ref|WP_004387938.1|	45.2	219	220	647	6.05e-56	187
k141_648_1	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	25.5	208	487	357	1.99e-13	70.5
k141_648_1	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	25.5	208	487	357	1.99e-13	70.5
k141_648_1	CARD|gb|AAD51347.1|ARO:3003067|smeS	26.9	193	487	467	2.24e-06	48.9
k141_61927_1	SARG|gi|488374619|ref|WP_002444004.1|	19.0	379	393	452	5.03e-22	96.3
k141_61927_1	SARG|gi|505177635|ref|WP_015364737.1|	21.4	378	393	451	1.01e-20	92.4
k141_61927_1	SARG|ZP_04679156	21.2	378	393	451	8.13e-20	89.7
k141_61927_1	SARG|gi|446573718|ref|WP_000651064.1|	21.2	378	393	451	8.13e-20	89.7
k141_61927_1	SARG|gi|686155635|ref|WP_031787393.1|	21.4	379	393	451	2.67e-19	88.2
k141_61927_1	SARG|HE999704.1.gene3064.p01	29.3	198	393	241	8.25e-19	84.0
k141_61927_1	SARG|gi|1006223553|ref|WP_061745579.1|	20.1	378	393	451	8.72e-19	86.7
k141_61927_1	SARG|gi|446573715|ref|WP_000651061.1|	20.1	378	393	451	1.17e-18	86.3
k141_61927_1	SARG|gi|686367913|ref|WP_031894914.1|	20.4	378	393	451	1.17e-18	86.3
k141_61927_1	SARG|gi|565830932|ref|WP_023914633.1|	20.4	378	393	451	1.57e-18	85.9
k141_103385_1	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	29.6	379	371	481	2.12e-43	155
k141_103385_1	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	30.3	379	371	451	2.46e-43	155
k141_103385_1	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	27.8	378	371	451	2.47e-40	147
k141_144632_1	SARG|gb|CAH14032.1|ARO:3004099|LpeA	25.6	246	258	355	3.65e-18	81.6
k141_144632_1	megares|MEG_3624|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_pumps|LPEA_1	25.6	246	258	355	3.65e-18	81.6
k141_144632_1	SARG|gi|489018151|ref|WP_002928665.1|	27.7	195	258	380	3.79e-15	73.2
k141_144632_1	SARG|gi|488872078|ref|WP_002784303.1|	25.5	200	258	385	7.11e-15	72.4
k141_144632_1	SARG|gi|488868725|ref|WP_002780964.1|	25.5	200	258	385	7.11e-15	72.4
k141_144632_1	SARG|gi|283794392|gb|EFC33136.1|	27.1	203	258	388	7.19e-15	72.4
k141_144632_1	SARG|gi|488899926|ref|WP_002811019.1|	25.0	200	258	385	2.39e-14	70.9
k141_144632_1	SARG|gi|488963196|ref|WP_002874220.1|	25.4	205	258	390	1.49e-13	68.6
k141_144632_1	SARG|gi|490435709|ref|WP_004306762.1|	25.4	205	258	390	2.73e-13	67.8
k141_144632_1	SARG|gi|490445525|ref|WP_004316446.1|	25.4	205	258	390	2.73e-13	67.8
k141_144632_2	SARG|gb|CAH14033.1|ARO:3004100|LpeB	27.3	461	460	1014	5.73e-37	143
k141_144632_2	SARG|gb|AAG05914|ARO:3004075|MuxC	24.3	457	460	1036	9.09e-35	137
k141_144632_2	SARG|gi|496334960|ref|WP_009044138.1|	25.6	464	460	1059	2.24e-34	135
k141_144632_2	SARG|gi|496340078|ref|WP_009049256.1|	25.4	464	460	1059	5.45e-34	134
k141_144632_2	SARG|gi|504907940|ref|WP_015095042.1|	25.4	464	460	1059	5.45e-34	134
k141_144632_2	SARG|gi|985599614|ref|WP_060839111.1|	25.4	464	460	1059	7.33e-34	134
k141_144632_2	SARG|gi|489544697|ref|WP_003449357.1|	24.8	464	460	1060	7.34e-34	134
k141_144632_2	SARG|gi|764528042|ref|WP_044407471.1|	25.2	464	460	1062	7.34e-34	134
k141_144632_2	SARG|YP_607927	24.6	464	460	1059	9.86e-34	134
k141_144632_2	SARG|gi|950551359|ref|WP_057425316.1|	25.0	464	460	1063	9.88e-34	134
k141_154969_1	SARG|gb|AAC75089.1|ARO:3003577|ugd	49.2	124	125	388	4.05e-31	112
k141_42176_2	SARG|gi|966403553|ref|WP_058447148.1|	49.7	398	389	1058	1.50e-125	386
k141_42176_2	SARG|gi|644964905|ref|WP_025385660.1|	49.2	398	389	1056	2.84e-125	385
k141_42176_2	SARG|gi|517405910|ref|WP_018578567.1|	49.8	400	389	1064	6.51e-125	384
k141_42176_2	SARG|gi|966461601|ref|WP_058493954.1|	50.0	398	389	1054	7.52e-125	384
k141_42176_2	SARG|gi|966476691|ref|WP_058507424.1|	49.7	398	389	1063	1.26e-124	384
k141_42176_2	SARG|gi|654933144|ref|WP_028383500.1|	50.3	398	389	1063	2.47e-124	383
k141_42176_2	SARG|CP000675.2.gene2723.p01	49.5	398	389	1050	3.77e-124	382
k141_42176_2	SARG|gi|966506160|ref|WP_058522806.1|	49.2	398	389	1066	5.13e-124	382
k141_42176_2	SARG|gi|966407319|ref|WP_058450725.1|	49.2	398	389	1062	6.66e-124	382
k141_42176_2	SARG|gi|966514950|ref|WP_058531469.1|	49.5	398	389	1055	8.15e-124	381
k141_83344_1	megares|MEG_8288|Drugs|beta-lactam|Mutant_porin_proteins|OMPA_1	45.1	91	331	374	5.46e-18	82.8
k141_83344_1	CARD|gb|CDO13836.1|ARO:3005044|OmpA	45.1	91	331	374	5.46e-18	82.8
k141_83474_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	26.3	190	192	219	4.64e-07	47.4
k141_11386_3	SARG|YP_002333394	30.7	179	271	323	7.22e-19	83.6
k141_11386_3	SARG|gi|749574782|ref|WP_040203616.1|	31.3	179	271	323	1.36e-18	82.8
k141_11386_3	SARG|AF310956.2.gene5.p01	30.7	179	271	323	1.87e-18	82.4
k141_11386_3	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	30.7	179	271	323	1.87e-18	82.4
k141_11386_3	SARG|AAY52004	30.2	179	271	322	2.53e-18	82.0
k141_11386_3	SARG|AY082011.1.gene6.p01	32.7	147	271	323	6.59e-18	80.9
k141_11386_3	SARG|gi|552942232|ref|WP_023043160.1|	32.7	147	271	323	9.03e-18	80.5
k141_11386_3	SARG|KF478993.1.gene2.p01	34.1	132	271	350	1.14e-17	80.5
k141_11386_3	SARG|AAD51059	31.3	147	271	323	5.94e-17	78.2
k141_11386_3	SARG|AAR37059	31.3	147	271	323	1.52e-16	77.0
k141_93817_1	CARD|gb|AAC75429.1|ARO:3000833|evgS	26.5	234	348	1197	6.08e-16	78.2
k141_93817_1	CARD|gb|AEX49906.1|ARO:3003583|basS	27.4	226	348	477	2.21e-15	75.9
k141_93817_1	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	36.2	94	348	230	2.90e-15	73.2
k141_93817_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.4	94	348	232	2.99e-15	73.2
k141_93817_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.8	95	348	228	3.83e-15	72.8
k141_93817_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.3	94	348	231	2.58e-14	70.5
k141_93817_1	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.4	91	348	219	3.98e-14	69.7
k141_93817_1	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.4	91	348	219	3.98e-14	69.7
k141_93817_1	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.4	91	348	220	4.04e-14	69.7
k141_93817_1	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.4	91	348	220	4.04e-14	69.7
k141_124632_1	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.8	189	188	1197	7.87e-25	99.8
k141_124632_2	SARG|gi|488243106|ref|WP_002314314.1|	29.0	162	453	492	1.17e-06	49.7
k141_124632_2	SARG|gi|488321355|ref|WP_002390740.1|	28.4	162	453	492	2.71e-06	48.5
k141_73019_2	SARG|NC_009085.4918693.p01	33.8	314	363	376	7.15e-41	146
k141_73019_2	SARG|gi|183210901|gb|ACC58299.1|	33.8	314	363	415	1.52e-40	146
k141_73019_2	SARG|NC_010400.5984386.p01	33.8	314	363	415	1.52e-40	146
k141_73019_2	SARG|NC_011586.7045443.p01	33.8	314	363	416	1.55e-40	146
k141_73019_2	NCBI|AAU10477.1|1|1|adeD|adeD|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_AdeD|AMR|efflux	31.1	341	363	374	1.42e-35	132
k141_73019_2	SARG|ABG77965	28.4	359	363	397	7.85e-35	130
k141_73019_2	SARG|gi|555116142|gb|ESM59081.1|	31.7	315	363	361	1.11e-34	129
k141_73019_2	SARG|gi|524234431|emb|CDA04526.1|	31.4	315	363	361	1.54e-34	129
k141_73019_2	SARG|CP000647.1.gene444.p01	31.4	315	363	397	2.09e-34	129
k141_73019_2	SARG|gi|573042590|emb|CDI16885.1|	31.4	315	363	417	2.87e-34	129
k141_73019_3	NCBI|AAN29241.1|1|1|bepE|bepE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepE|AMR|efflux	46.8	237	242	1051	1.34e-67	224
k141_73019_3	CARD|gb|ABS43151.1|ARO:3000784|cmeB	45.8	240	242	1040	1.75e-67	223
k141_73019_3	NCBI|WP_254563251.1|1|1|cmeB_RE|cmeB_RE|efflux|2|FLORFENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_CmeB,_ciprofloxacin_and_phenicol_resistance_type|AMR|multidrug	46.3	242	242	1039	5.28e-65	216
k141_73019_3	SARG|gi|492246796|ref|WP_005788492.1|	44.8	239	242	1059	6.48e-63	211
k141_73019_3	SARG|gi|803453816|ref|WP_046068030.1|	44.8	239	242	1059	6.48e-63	211
k141_73019_3	SARG|gi|489283474|ref|WP_003191086.1|	44.8	239	242	1059	6.48e-63	211
k141_73019_3	SARG|gi|512735233|ref|WP_016493075.1|	44.4	239	242	1062	6.54e-63	211
k141_73019_3	SARG|gi|730317804|ref|WP_033983157.1|	43.9	239	242	1062	1.23e-62	210
k141_73019_3	SARG|gi|489252358|ref|WP_003160388.1|	43.9	239	242	1062	1.68e-62	209
k141_73019_3	SARG|gi|757686578|ref|WP_042917070.1|	43.9	239	242	1062	1.68e-62	209
k141_52686_1	CARD|gb|AAC75135.2|ARO:3000792|mdtA	26.8	194	330	415	5.90e-10	58.9
k141_42611_1	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	43.8	518	493	1162	8.58e-128	398
k141_42611_1	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	43.9	522	493	1186	7.55e-125	391
k141_42611_1	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	43.9	522	493	1186	7.55e-125	391
k141_124762_3	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	41.2	68	68	229	1.51e-13	61.2
k141_124762_3	CARD|gb|AAC73788.1|ARO:3003841|kdpE	33.8	68	68	225	5.49e-10	51.6
k141_124762_3	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	33.8	65	68	225	1.46e-09	50.4
k141_135199_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	37.5	523	521	1024	2.15e-107	342
k141_135199_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	37.5	523	521	1024	2.15e-107	342
k141_135199_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	37.5	523	521	1024	2.15e-107	342
k141_135199_1	SARG|gb|CAA53189|ARO:3000521|mupA	37.5	523	521	1024	2.15e-107	342
k141_135199_1	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	37.7	525	521	1033	1.99e-103	332
k141_135199_1	SARG|gb|AEY83581|ARO:3000510|mupB	37.7	525	521	1033	1.99e-103	332
k141_135199_1	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	34.1	542	521	1107	8.23e-94	307
k141_135199_1	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	34.1	542	521	1107	8.23e-94	307
k141_21754_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.3	218	232	231	7.11e-35	123
k141_21754_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	34.3	213	232	219	1.36e-31	114
k141_21754_2	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.1	214	232	219	2.08e-30	111
k141_21754_2	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.1	214	232	219	2.92e-30	110
k141_21754_2	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.1	214	232	220	2.99e-30	110
k141_21754_2	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.1	214	232	220	4.20e-30	110
k141_21754_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	31.8	220	232	232	3.05e-29	108
k141_21754_2	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	29.9	224	232	231	6.29e-28	105
k141_21754_2	CARD|gb|AAG06465.1|ARO:3005063|cprR	28.2	206	232	223	5.60e-27	102
k141_21754_2	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	29.5	220	232	233	1.53e-24	96.3
k141_124876_1	CARD|gb|AAC75429.1|ARO:3000833|evgS	34.2	219	220	1197	1.12e-28	112
k141_124896_2	SARG|gb|APB03220.1|ARO:3003987|VatI	36.3	113	188	210	6.22e-13	63.5
k141_124896_2	SARG|AF139725.gene.p01	32.6	129	188	214	1.21e-11	60.1
k141_124896_2	NCBI|WP_063856931.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	32.6	129	188	214	1.21e-11	60.1
k141_124896_2	NCBI|WP_063856932.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	32.6	129	188	214	1.21e-11	60.1
k141_124896_2	NCBI|WP_063856933.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	32.6	129	188	214	1.21e-11	60.1
k141_124896_2	NCBI|WP_063856934.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	32.6	129	188	214	1.21e-11	60.1
k141_124896_2	SARG|AAG21695	32.6	129	188	214	1.21e-11	60.1
k141_124896_2	SARG|AAK91782	32.6	129	188	214	1.21e-11	60.1
k141_124896_2	SARG|AAF24171	30.4	138	188	214	1.68e-11	59.7
k141_124896_2	SARG|M58472.1.gene1.p01	38.9	95	188	209	1.09e-10	57.4
k141_125046_2	CARD|gb|AAC75429.1|ARO:3000833|evgS	31.2	215	216	1197	6.29e-28	109
k141_145495_3	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	46.3	160	158	703	1.08e-35	129
k141_43111_2	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.8	122	141	1197	7.83e-16	72.0
k141_43111_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.0	124	141	219	1.05e-09	53.5
k141_43111_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.4	108	141	232	1.17e-09	53.5
k141_43111_2	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.5	124	141	219	2.01e-09	52.8
k141_43111_2	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.5	124	141	219	2.01e-09	52.8
k141_43111_2	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.5	124	141	220	2.02e-09	52.8
k141_43111_2	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.5	124	141	220	2.79e-09	52.4
k141_43111_2	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.8	124	141	220	4.97e-08	48.9
k141_43111_2	CARD|gb|AAG06465.1|ARO:3005063|cprR	25.4	114	141	223	1.80e-07	47.4
k141_43111_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	26.2	107	141	231	5.88e-06	43.1
k141_135546_1	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.6	339	348	655	2.19e-57	196
k141_135546_1	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.6	339	348	655	2.19e-57	196
k141_135546_1	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.6	339	348	655	2.19e-57	196
k141_135546_1	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.6	339	348	655	3.04e-57	195
k141_135546_1	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.6	339	348	655	3.04e-57	195
k141_135546_1	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.6	339	348	655	3.04e-57	195
k141_135546_1	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.6	339	348	655	3.04e-57	195
k141_135546_1	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.6	339	348	655	3.04e-57	195
k141_135546_1	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.6	339	348	655	3.04e-57	195
k141_135546_1	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.6	339	348	655	4.22e-57	195
k141_2208_1	SARG|gi|671541568|ref|WP_031525212.1|	33.3	96	488	648	3.78e-07	51.6
k141_63538_1	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	28.1	192	261	346	7.44e-11	60.5
k141_73742_3	SARG|gb|AAG05914|ARO:3004075|MuxC	23.9	280	286	1036	3.67e-13	68.6
k141_94951_2	SARG|AAN28721	67.6	74	426	108	3.55e-31	114
k141_125740_2	SARG|gi|1043941253|emb|SBY03087.1|	25.2	436	424	646	1.38e-15	77.8
k141_125740_2	SARG|gi|983413012|ref|WP_060578893.1|	25.0	436	424	646	1.83e-15	77.4
k141_125740_2	SARG|gi|694073280|ref|WP_032419142.1|	25.0	436	424	646	2.44e-15	77.0
k141_125740_2	SARG|gi|1031824807|ref|WP_064152164.1|	25.0	436	424	646	2.44e-15	77.0
k141_125740_2	SARG|gi|1031825849|ref|WP_064152930.1|	25.0	436	424	646	2.44e-15	77.0
k141_125740_2	SARG|gi|1031822889|ref|WP_064150402.1|	25.2	436	424	646	3.25e-15	76.6
k141_125740_2	SARG|gi|749639729|ref|WP_040241690.1|	25.0	436	424	646	3.25e-15	76.6
k141_125740_2	SARG|gi|490306253|ref|WP_004201358.1|	25.2	436	424	646	3.25e-15	76.6
k141_125740_2	SARG|gi|644804533|ref|WP_025368306.1|	24.7	433	424	646	3.25e-15	76.6
k141_125740_2	SARG|gi|1000904163|ref|WP_061155197.1|	25.2	436	424	646	3.25e-15	76.6
k141_125740_3	SARG|gi|513039047|ref|WP_016506940.1|	33.7	92	104	372	2.22e-07	46.2
k141_125740_3	SARG|gi|447124500|ref|WP_001201756.1|	32.6	95	104	372	5.65e-07	45.1
k141_125740_3	SARG|gi|805303886|ref|WP_046093569.1|	32.6	95	104	372	5.65e-07	45.1
k141_125740_3	SARG|gi|447124490|ref|WP_001201746.1|	33.7	92	104	372	5.65e-07	45.1
k141_125740_3	SARG|gi|554679504|ref|WP_023180493.1|	32.6	95	104	372	7.71e-07	44.7
k141_125740_3	SARG|gi|555268036|ref|WP_023249476.1|	32.6	92	104	372	1.05e-06	44.3
k141_125740_3	SARG|gi|447124501|ref|WP_001201757.1|	32.6	92	104	372	1.05e-06	44.3
k141_125740_3	SARG|gi|554685679|ref|WP_023185566.1|	32.6	92	104	372	1.05e-06	44.3
k141_125740_3	SARG|gi|526247417|ref|WP_020843768.1|	32.6	92	104	372	1.05e-06	44.3
k141_125740_3	SARG|gi|1005290618|ref|WP_061584272.1|	32.6	92	104	344	1.42e-06	43.9
k141_33408_1	NCBI|AAN33534.1|1|1|bepG|bepG|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepG|AMR|efflux	46.6	350	346	1074	2.49e-92	296
k141_33408_1	NCBI|AAN29241.1|1|1|bepE|bepE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepE|AMR|efflux	45.0	351	346	1051	9.42e-87	281
k141_33408_1	CARD|gb|ABS43151.1|ARO:3000784|cmeB	44.2	351	346	1040	2.19e-85	277
k141_33408_1	SARG|gi|966461601|ref|WP_058493954.1|	43.6	360	346	1054	4.81e-84	273
k141_33408_1	SARG|gi|966432980|ref|WP_058473413.1|	43.3	360	346	1070	5.50e-83	271
k141_33408_1	SARG|gi|966511896|ref|WP_058528450.1|	43.3	360	346	1061	3.53e-82	268
k141_33408_1	SARG|gi|654933144|ref|WP_028383500.1|	42.5	360	346	1063	4.98e-82	268
k141_33408_1	SARG|CP000675.2.gene2723.p01	42.8	360	346	1050	8.41e-82	267
k141_33408_1	SARG|gi|966407319|ref|WP_058450725.1|	42.2	360	346	1062	6.61e-81	265
k141_33408_1	SARG|gi|966476691|ref|WP_058507424.1|	42.5	360	346	1063	9.22e-81	265
k141_12607_1	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	31.1	103	117	368	2.93e-11	57.8
k141_12607_1	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	30.1	103	117	367	7.46e-11	56.6
k141_12607_1	CARD|gb|AAD51347.1|ARO:3003067|smeS	30.4	112	117	467	3.26e-09	52.0
k141_12607_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	27.8	223	229	228	4.05e-19	81.6
k141_12607_2	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	22.5	231	229	232	1.79e-07	49.3
k141_12607_2	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	24.7	235	229	232	1.10e-06	47.0
k141_12607_2	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	24.7	235	229	232	1.49e-06	46.6
k141_12607_2	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	24.7	235	229	232	2.71e-06	45.8
k141_12607_2	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	24.7	235	229	232	4.95e-06	45.1
k141_43867_1	ResF|mre(A)_1_U92073_1	40.7	86	91	310	6.67e-14	63.9
k141_43867_1	SARG|gb|AAB64408.1|ARO:3007050|mreA	40.7	86	91	311	6.70e-14	63.9
k141_43916_1	CARD|gb|AAC75429.1|ARO:3000833|evgS	31.0	394	897	1197	9.29e-46	177
k141_43916_1	CARD|gb|AAD51347.1|ARO:3003067|smeS	28.1	224	897	467	7.27e-14	73.9
k141_43916_1	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.3	123	897	219	1.53e-08	55.1
k141_43916_1	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.3	123	897	219	1.53e-08	55.1
k141_43916_1	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.3	123	897	220	1.55e-08	55.1
k141_43916_1	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.3	123	897	220	2.09e-08	54.7
k141_43916_1	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.5	123	897	220	9.25e-08	52.8
k141_43916_1	CARD|gb|ADM92605.1|ARO:3000553|adeR	28.1	135	897	247	9.69e-07	50.1
k141_43916_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	28.7	122	897	232	1.51e-06	49.3
k141_43916_1	CARD|gb|ATC67679.1|ARO:3000838|arlR	26.8	123	897	219	5.77e-06	47.4
k141_116385_2	SARG|gi|488120365|ref|WP_002191762.1|	31.3	150	151	309	7.57e-16	71.6
k141_116385_2	SARG|gi|445996724|ref|WP_000074579.1|	30.7	150	151	309	1.44e-15	70.9
k141_116385_2	SARG|gi|445996729|ref|WP_000074584.1|	30.7	150	151	309	1.44e-15	70.9
k141_116385_2	SARG|gi|1043490477|ref|WP_065382463.1|	30.7	150	151	309	1.44e-15	70.9
k141_116385_2	SARG|gi|445996726|ref|WP_000074581.1|	30.7	150	151	309	1.44e-15	70.9
k141_116385_2	SARG|gi|884875933|emb|CKG93789.1|	30.7	150	151	309	1.44e-15	70.9
k141_116385_2	SARG|gi|445996723|ref|WP_000074578.1|	30.7	150	151	309	1.44e-15	70.9
k141_116385_2	SARG|gi|507054395|ref|WP_016125339.1|	30.7	150	151	309	1.44e-15	70.9
k141_116385_2	SARG|gi|445996722|ref|WP_000074577.1|	30.7	150	151	309	1.44e-15	70.9
k141_116385_2	SARG|gi|507050365|ref|WP_016121371.1|	30.7	150	151	309	1.99e-15	70.5
k141_33963_3	SARG|AB082569.2.gene1.p01	29.7	145	164	213	7.06e-15	68.2
k141_33963_3	SARG|X53797.1.gene1.p01	29.7	145	164	213	1.37e-14	67.4
k141_33963_3	SARG|CAD57199	30.3	145	164	213	3.69e-14	66.2
k141_33963_3	SARG|X53796.1.gene1.p01	29.7	145	164	213	2.67e-13	63.9
k141_33963_3	SARG|YP_001966224	29.0	145	164	213	1.37e-12	62.0
k141_116396_2	CARD|gb|AAC75429.1|ARO:3000833|evgS	30.5	390	1030	1197	8.78e-44	172
k141_116396_2	CARD|gb|ADM92606.1|ARO:3000549|adeS	29.1	227	1030	361	1.86e-17	84.3
k141_116396_2	CARD|gb|ADM92605.1|ARO:3000553|adeR	34.2	114	1030	247	6.80e-11	62.8
k141_116396_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.6	116	1030	232	6.48e-09	56.6
k141_116396_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	34.3	102	1030	231	8.62e-09	56.2
k141_116396_2	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	30.7	114	1030	223	1.90e-08	55.1
k141_116396_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	27.2	114	1030	228	4.11e-06	48.1
k141_54370_2	SARG|gb|ADZ12699.1|ARO:3005091|RanA	58.1	248	257	258	3.48e-102	296
k141_54370_2	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.9	219	257	574	3.16e-14	70.9
k141_54370_2	SARG|M57437.gene.p01	25.0	196	257	548	3.29e-09	55.8
k141_54370_2	SARG|gi|817536927|ref|WP_046586836.1|	23.4	197	257	492	7.59e-09	54.7
k141_54370_2	SARG|gi|494215524|ref|WP_007131565.1|	20.7	213	257	492	1.83e-08	53.5
k141_54370_2	SARG|AJ579365.gene.p01	25.2	214	257	492	2.45e-08	53.1
k141_54370_2	SARG|gi|953356378|ref|WP_058006334.1|	22.5	200	257	492	4.41e-08	52.4
k141_54370_2	SARG|gi|926250866|ref|WP_053589133.1|	21.6	213	257	492	5.91e-08	52.0
k141_54370_2	SARG|gb|AGN74946|ARO:3003749|salA	20.1	264	257	541	8.22e-08	51.6
k141_54370_2	SARG|gi|499132967|ref|WP_010860999.1|	21.6	213	257	492	1.90e-07	50.4
k141_54370_3	SARG|gb|ADZ12700.1|ARO:3005090|RanB	58.3	48	49	253	8.39e-12	55.8
k141_23142_1	SARG|gb|AAG05915.1|ARO:3004074|MuxB	32.6	313	318	1043	4.51e-48	171
k141_23142_1	CARD|gb|AAC75136.1|ARO:3000793|mdtB	33.2	313	318	1040	6.11e-46	165
k141_23142_1	SARG|YP_001186705	28.3	311	318	1017	8.73e-37	139
k141_23142_1	NCBI|WP_254563251.1|1|1|cmeB_RE|cmeB_RE|efflux|2|FLORFENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_CmeB,_ciprofloxacin_and_phenicol_resistance_type|AMR|multidrug	25.3	320	318	1039	7.16e-29	115
k141_23142_1	SARG|gi|757800059|ref|WP_043017261.1|	28.8	320	318	1038	1.77e-28	114
k141_23142_1	CARD|gb|AAX14802.1|ARO:3000781|adeJ	26.0	315	318	1058	1.78e-28	114
k141_23142_1	SARG|gi|507086511|ref|WP_016157252.1|	28.4	320	318	1038	5.93e-28	113
k141_23142_1	SARG|gi|489922738|ref|WP_003826085.1|	29.1	320	318	1038	5.93e-28	113
k141_23142_1	SARG|YP_002847505	29.1	320	318	1038	5.93e-28	113
k141_23142_1	SARG|gi|754957138|ref|WP_042313243.1|	28.4	320	318	1038	1.98e-27	111
k141_23142_2	CARD|gb|AAG03546.1|ARO:3003679|TriA	24.9	345	342	383	2.64e-22	95.5
k141_23142_2	SARG|YP_002706076	25.2	337	342	394	8.78e-21	91.3
k141_23142_2	SARG|YP_002029850	24.6	342	342	393	1.61e-20	90.5
k141_23142_2	SARG|CAG34256	25.2	337	342	394	8.62e-19	85.5
k141_23142_2	SARG|CAG34249	24.3	337	342	394	2.14e-18	84.3
k141_23142_2	SARG|gi|490836655|ref|WP_004698731.1|	25.4	173	342	445	9.09e-09	55.5
k141_23142_2	SARG|gi|487980711|ref|WP_002053440.1|	24.9	173	342	446	8.95e-08	52.4
k141_23142_2	SARG|gi|490848588|ref|WP_004710651.1|	24.9	173	342	446	8.95e-08	52.4
k141_23142_2	SARG|gi|518287882|ref|WP_019458090.1|	24.9	173	342	446	8.95e-08	52.4
k141_23142_2	SARG|gi|1032317555|ref|WP_064192057.1|	26.3	152	342	446	2.10e-07	51.2
k141_23142_3	SARG|gi|495003549|ref|WP_007729563.1|	25.4	122	156	496	2.88e-11	59.3
k141_23142_3	SARG|gi|742388728|ref|WP_038867854.1|	25.4	122	156	496	2.88e-11	59.3
k141_23142_3	SARG|gi|742390648|ref|WP_038869774.1|	25.4	122	156	496	2.88e-11	59.3
k141_23214_2	CARD|gb|AAD51348.1|ARO:3003066|smeR	34.2	117	1139	229	3.19e-14	72.4
k141_23214_2	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	21.5	214	1139	367	1.33e-12	69.7
k141_23214_2	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	21.5	214	1139	368	1.34e-12	69.7
k141_23214_2	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	34.6	104	1139	239	2.55e-12	67.0
k141_23214_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	32.7	104	1139	235	7.95e-12	65.5
k141_34080_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.2	224	229	219	2.00e-49	160
k141_34080_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.5	232	229	231	2.45e-38	132
k141_34080_2	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.4	230	229	231	2.45e-38	132
k141_34080_2	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.5	232	229	231	2.45e-38	132
k141_34080_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.0	230	229	231	4.86e-38	131
k141_34080_2	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.4	230	229	231	6.86e-38	130
k141_34080_2	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.5	230	229	231	9.66e-38	130
k141_34080_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.0	235	229	232	1.40e-37	130
k141_34080_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.0	235	229	232	1.40e-37	130
k141_34080_2	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.1	230	229	231	2.71e-37	129
k141_34080_3	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.4	110	469	370	3.46e-09	57.4
k141_34080_3	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.1	88	469	365	1.37e-07	52.4
k141_157406_3	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	30.6	111	254	225	2.43e-06	46.2
k141_157406_3	CARD|gb|AAC73788.1|ARO:3003841|kdpE	30.9	110	254	225	4.42e-06	45.4
k141_54858_2	SARG|gi|502669352|ref|WP_012905216.1|	47.4	152	151	648	1.71e-38	136
k141_54858_2	SARG|gi|1035706844|ref|WP_064548272.1|	46.1	152	151	648	8.42e-38	134
k141_54858_2	SARG|gi|803568669|ref|WP_046077412.1|	45.4	152	151	648	1.16e-37	134
k141_54858_2	SARG|gi|446110352|ref|WP_000188207.1|	45.4	152	151	648	1.16e-37	134
k141_54858_2	SARG|YP_002382193	45.4	152	151	648	1.16e-37	134
k141_54858_2	SARG|gi|803575554|ref|WP_046081557.1|	45.4	152	151	648	1.16e-37	134
k141_54858_2	SARG|gi|446110351|ref|WP_000188206.1|	45.4	152	151	648	1.16e-37	134
k141_54858_2	SARG|gi|736472622|ref|WP_034494292.1|	46.1	152	151	648	3.01e-37	133
k141_54858_2	SARG|gi|1035670474|ref|WP_064517458.1|	46.1	152	151	648	4.13e-37	132
k141_54858_2	SARG|gi|1035717981|ref|WP_064557480.1|	46.1	152	151	648	4.13e-37	132
k141_95983_1	CARD|gb|AAC73788.1|ARO:3003841|kdpE	25.4	181	380	225	3.86e-12	64.3
k141_95983_1	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	25.1	179	380	225	7.07e-12	63.5
k141_95983_1	CARD|gb|AAC75429.1|ARO:3000833|evgS	30.1	123	380	1197	1.37e-09	58.9
k141_34624_1	SARG|gb|APB03219.1|ARO:3003986|TaeA	42.6	61	62	648	9.41e-11	53.9
k141_34624_1	SARG|gi|488321355|ref|WP_002390740.1|	36.8	57	62	492	1.27e-07	45.1
k141_34624_1	SARG|gi|488231473|ref|WP_002302681.1|	35.1	57	62	492	4.44e-07	43.5
k141_34624_1	SARG|gi|488216250|ref|WP_002287458.1|	35.1	57	62	492	4.44e-07	43.5
k141_34624_1	SARG|gi|488247627|ref|WP_002318835.1|	35.1	57	62	492	4.44e-07	43.5
k141_34624_1	SARG|AY004350.gene.p01	35.1	57	62	492	4.44e-07	43.5
k141_34624_1	SARG|gi|488243106|ref|WP_002314314.1|	33.3	57	62	492	1.14e-06	42.4
k141_34624_1	SARG|gb|AGN74946|ARO:3003749|salA	29.0	62	62	541	1.14e-06	42.4
k141_34624_1	SARG|U82085.gene.p01	32.7	52	62	552	4.03e-06	40.8
k141_64953_1	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	30.6	85	129	307	1.32e-10	56.2
k141_64953_1	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	32.4	71	129	574	1.71e-06	44.7
k141_13566_1	SARG|gi|817122037|ref|WP_046494699.1|	46.2	145	153	613	2.38e-35	127
k141_13566_1	SARG|gi|943938624|ref|WP_055567802.1|	44.0	150	153	602	3.11e-35	127
k141_13566_1	SARG|gi|860594225|ref|WP_048475168.1|	44.3	149	153	620	4.65e-35	127
k141_13566_1	SARG|gi|695842130|ref|WP_032755430.1|	45.5	145	153	603	8.13e-35	126
k141_13566_1	SARG|gi|505420018|ref|WP_015607120.1|	45.5	145	153	603	8.13e-35	126
k141_13566_1	SARG|gi|497748188|ref|WP_010062372.1|	43.4	145	153	605	2.13e-34	125
k141_13566_1	SARG|AF170880.4.gene1.p01	50.0	136	153	615	2.23e-34	125
k141_13566_1	SARG|gi|754608317|ref|WP_041998010.1|	44.8	145	153	612	4.15e-34	124
k141_13566_1	SARG|gi|926351744|ref|WP_053683383.1|	44.8	145	153	648	4.71e-34	124
k141_13566_1	SARG|gi|944470764|ref|WP_055701183.1|	44.0	150	153	601	5.45e-34	124
k141_96222_1	SARG|YP_992987	22.4	214	239	1041	5.67e-08	52.0
k141_96222_1	SARG|ZP_03453095	22.4	214	239	1043	5.67e-08	52.0
k141_96222_1	SARG|AAC27754	22.4	214	239	1043	5.67e-08	52.0
k141_96222_1	SARG|ZP_01769103	22.4	214	239	1043	5.67e-08	52.0
k141_127098_2	CARD|gb|AAG03548.1|ARO:3003681|TriC	26.8	605	619	1015	1.73e-62	222
k141_127098_2	SARG|gb|AAG07064.1|ARO:3003693|mexK	27.2	610	619	1025	9.49e-57	206
k141_127098_2	CARD|gb|AAC75136.1|ARO:3000793|mdtB	23.4	603	619	1040	8.01e-36	143
k141_127098_2	SARG|gb|AAG05915.1|ARO:3004074|MuxB	21.8	605	619	1043	1.06e-32	133
k141_127098_2	SARG|gi|966514950|ref|WP_058531469.1|	24.1	615	619	1055	1.07e-32	133
k141_127098_2	SARG|gi|966511896|ref|WP_058528450.1|	23.9	615	619	1061	1.08e-32	133
k141_127098_2	NCBI|AAN33534.1|1|1|bepG|bepG|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepG|AMR|efflux	23.5	620	619	1074	1.42e-31	130
k141_127098_2	SARG|gi|644964905|ref|WP_025385660.1|	24.1	615	619	1056	5.86e-31	128
k141_127098_2	SARG|gi|505264501|ref|WP_015451603.1|	23.9	595	619	1031	7.65e-31	127
k141_127098_2	SARG|gi|487969243|ref|WP_002042236.1|	23.9	595	619	1031	7.65e-31	127
k141_45252_4	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	27.5	244	399	392	7.98e-20	89.4
k141_158003_2	SARG|gi|391256340|gb|EIQ15472.1|	25.3	190	479	410	9.86e-10	59.3
k141_158003_2	SARG|gi|447059779|ref|WP_001137035.1|	24.7	190	479	410	1.74e-09	58.5
k141_158003_2	SARG|gi|567973331|ref|WP_024044846.1|	24.7	190	479	410	2.30e-09	58.2
k141_158003_2	SARG|YP_002384189	24.7	190	479	410	2.30e-09	58.2
k141_158003_2	SARG|gi|447059742|ref|WP_001136998.1|	24.7	190	479	410	2.30e-09	58.2
k141_158003_2	SARG|gi|487376640|ref|WP_001649706.1|	26.8	164	479	410	2.30e-09	58.2
k141_158003_2	SARG|gi|486189080|ref|WP_001542462.1|	24.7	190	479	410	2.30e-09	58.2
k141_158003_2	SARG|gi|693143742|ref|WP_032283697.1|	24.7	190	479	410	2.30e-09	58.2
k141_158003_2	SARG|P39386	24.7	190	479	410	2.30e-09	58.2
k141_158003_2	SARG|gi|447059738|ref|WP_001136994.1|	24.7	190	479	410	2.30e-09	58.2
k141_65453_4	CARD|gb|AEX49906.1|ARO:3003583|basS	32.2	87	95	477	1.51e-06	43.5
k141_117373_1	NCBI|AAN29241.1|1|1|bepE|bepE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepE|AMR|efflux	39.4	763	804	1051	6.33e-157	483
k141_117373_1	SARG|gi|950763791|ref|WP_057508902.1|	37.3	775	804	1048	3.97e-153	473
k141_117373_1	SARG|gi|756166813|ref|WP_042615010.1|	36.9	769	804	1048	6.85e-150	465
k141_117373_1	SARG|gi|951185348|ref|WP_057663064.1|	36.5	764	804	1045	9.55e-149	462
k141_117373_1	SARG|gi|916992013|ref|WP_051598725.1|	36.1	775	804	1062	8.74e-146	454
k141_117373_1	SARG|gi|694076105|ref|WP_032421853.1|	36.7	765	804	1036	3.86e-144	449
k141_117373_1	SARG|YP_002706077	35.7	767	804	1040	4.23e-144	449
k141_117373_1	SARG|CAC14595	35.9	767	804	1040	1.17e-143	448
k141_117373_1	SARG|CP000647.1.gene3710.p01	36.5	765	804	1036	2.93e-143	447
k141_117373_1	SARG|gi|692318199|ref|WP_032129007.1|	35.6	767	804	1040	3.21e-143	447
k141_117373_2	SARG|gi|686943314|gb|KGD21341.1|	42.7	96	134	466	7.14e-11	57.4
k141_117373_2	SARG|ZP_02108902	42.7	96	134	513	7.26e-11	57.4
k141_117373_2	SARG|gi|714542454|gb|KGV72991.1|	42.7	96	134	516	7.27e-11	57.4
k141_117373_2	SARG|YP_002896634	42.7	96	134	516	7.27e-11	57.4
k141_117373_2	SARG|gi|686913144|gb|KGC91538.1|	42.7	96	134	516	7.27e-11	57.4
k141_117373_2	SARG|gi|714540353|gb|KGV70892.1|	42.7	96	134	516	7.27e-11	57.4
k141_117373_2	SARG|gi|686889105|gb|KGC67817.1|	42.7	96	134	516	7.27e-11	57.4
k141_117373_2	SARG|YP_001066170	42.7	96	134	516	7.27e-11	57.4
k141_117373_2	SARG|gi|701276740|gb|AIV62560.1|	42.7	96	134	516	7.27e-11	57.4
k141_117373_2	SARG|YP_001058926	42.7	96	134	516	7.27e-11	57.4
k141_137767_3	SARG|gb|APB03220.1|ARO:3003987|VatI	37.8	119	195	210	1.43e-14	68.2
k141_137767_3	SARG|GQ205627.2.gene3.p01	39.0	118	195	216	5.80e-14	66.6
k141_137767_3	SARG|YP_001779894	34.7	124	195	212	7.58e-14	66.2
k141_137767_3	SARG|YP_001389621	33.9	124	195	212	2.02e-13	65.1
k141_137767_3	SARG|U19459.gene.p01	33.6	116	195	212	3.87e-13	64.3
k141_137767_3	SARG|YP_001785579	33.9	124	195	212	3.87e-13	64.3
k141_137767_3	SARG|YP_002861121	32.9	143	195	212	1.03e-12	63.2
k141_137767_3	SARG|AF015628.1.gene2.p01	46.7	60	195	212	9.36e-11	57.8
k141_14076_2	SARG|gb|WP_010896559.1|ARO:3004643|Erm(K)	32.8	189	267	284	2.37e-21	89.7
k141_14076_2	SARG|P07287	28.6	206	267	381	8.33e-17	78.2
k141_14076_2	megares|MEG_2827|Drugs|MLS|23S_rRNA_methyltransferases|ERME_1	28.6	206	267	381	8.33e-17	78.2
k141_14076_2	SARG|Q04720	28.8	184	267	287	3.16e-15	72.8
k141_14076_2	SARG|M29832.gene.p01	28.8	184	267	287	3.16e-15	72.8
k141_14076_2	SARG|P45438	29.0	186	267	287	3.83e-14	69.7
k141_14076_2	SARG|gi|752296432|ref|WP_041152457.1|	26.1	211	267	245	4.95e-12	63.2
k141_14076_2	SARG|1112175A	26.7	206	267	370	3.54e-11	61.6
k141_127860_2	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	31.2	234	255	481	1.25e-28	112
k141_127860_2	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	30.9	230	255	451	4.52e-27	107
k141_127860_2	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	28.9	232	255	451	1.50e-25	103
k141_4731_1	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.4	229	227	231	1.04e-39	135
k141_4731_1	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.7	229	227	231	1.47e-39	135
k141_4731_1	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	35.4	229	227	231	8.21e-39	133
k141_4731_1	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.4	229	227	231	8.21e-39	133
k141_4731_1	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.4	229	227	231	1.16e-38	132
k141_4731_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.1	228	227	231	1.41e-36	127
k141_4731_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	33.2	229	227	232	1.45e-36	127
k141_4731_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	33.2	229	227	232	1.45e-36	127
k141_4731_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	35.6	233	227	232	2.88e-36	126
k141_4731_1	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	32.9	228	227	229	3.22e-34	121
k141_14414_1	SARG|gb|AAC75089.1|ARO:3003577|ugd	28.1	359	437	388	1.22e-41	150
k141_148231_1	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.0	313	427	655	6.62e-52	183
k141_148231_1	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.0	313	427	655	6.62e-52	183
k141_148231_1	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.7	313	427	655	2.41e-51	182
k141_148231_1	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.7	313	427	655	2.41e-51	182
k141_148231_1	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.7	313	427	655	2.41e-51	182
k141_148231_1	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.7	313	427	655	2.41e-51	182
k141_148231_1	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.7	313	427	655	2.41e-51	182
k141_148231_1	SARG|gb|AKA86814|ARO:3003746|optrA	37.7	313	427	655	2.41e-51	182
k141_148231_1	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.7	313	427	655	4.61e-51	181
k141_148231_1	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.7	313	427	655	4.61e-51	181
k141_46670_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	25.4	228	520	370	1.81e-14	73.9
k141_46670_1	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	25.5	231	520	365	3.13e-14	73.2
k141_76632_2	SARG|gi|515955949|ref|WP_017386532.1|	26.8	235	267	406	9.85e-26	103
k141_76632_2	SARG|gi|727726402|ref|WP_033847639.1|	26.7	266	267	406	9.85e-26	103
k141_76632_2	SARG|gi|746192777|ref|WP_039250898.1|	27.1	266	267	406	1.36e-25	103
k141_76632_2	SARG|gi|490838406|ref|WP_004700481.1|	27.1	266	267	406	1.36e-25	103
k141_76632_2	SARG|gi|759552006|ref|WP_043271822.1|	29.5	264	267	410	1.41e-25	103
k141_76632_2	SARG|gi|497308478|ref|WP_009622695.1|	29.5	264	267	410	1.41e-25	103
k141_76632_2	SARG|gi|749314681|ref|WP_040138758.1|	27.3	238	267	405	1.85e-25	102
k141_76632_2	SARG|gi|690992826|ref|WP_031962668.1|	27.1	266	267	406	1.87e-25	102
k141_76632_2	SARG|gi|639919893|ref|WP_024762275.1|	29.2	264	267	411	1.96e-25	102
k141_76632_2	SARG|gi|490978871|ref|WP_004840634.1|	27.1	266	267	405	2.55e-25	102
k141_108344_1	CARD|gb|AAC75429.1|ARO:3000833|evgS	31.8	286	427	1197	9.64e-31	124
k141_108344_1	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	35.4	113	427	239	5.51e-15	73.2
k141_108344_1	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.0	115	427	219	1.07e-11	63.2
k141_108344_1	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.0	115	427	219	1.07e-11	63.2
k141_108344_1	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.0	115	427	220	1.09e-11	63.2
k141_108344_1	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	34.7	118	427	225	1.17e-11	63.2
k141_108344_1	CARD|gb|AAC73788.1|ARO:3003841|kdpE	34.7	118	427	225	1.17e-11	63.2
k141_108344_1	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.0	115	427	220	1.47e-11	62.8
k141_108344_1	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.0	125	427	220	3.63e-11	61.6
k141_108344_1	CARD|gb|AAG06465.1|ARO:3005063|cprR	33.6	116	427	223	1.70e-10	59.7
k141_139006_2	SARG|gb|CAH14033.1|ARO:3004100|LpeB	27.5	600	623	1014	4.19e-54	198
k141_139006_2	SARG|YP_606823	25.8	527	623	1011	3.93e-48	180
k141_139006_2	SARG|YP_001670703	24.7	570	623	1014	4.23e-47	177
k141_139006_2	SARG|YP_001266290	24.9	570	623	1014	7.64e-47	176
k141_139006_2	SARG|gi|492246796|ref|WP_005788492.1|	27.7	613	623	1059	1.15e-45	173
k141_139006_2	SARG|gi|803453816|ref|WP_046068030.1|	27.7	613	623	1059	1.15e-45	173
k141_139006_2	SARG|gi|751651551|ref|WP_041118420.1|	26.7	619	623	1059	1.15e-45	173
k141_139006_2	SARG|gi|496340078|ref|WP_009049256.1|	26.8	619	623	1059	1.55e-45	172
k141_139006_2	SARG|gi|489294780|ref|WP_003202298.1|	27.5	619	623	1059	1.55e-45	172
k141_139006_2	SARG|YP_371056	26.8	623	623	1066	1.56e-45	172
k141_76806_1	SARG|gb|AAG07064.1|ARO:3003693|mexK	27.1	506	517	1025	7.20e-47	174
k141_76806_1	CARD|gb|AAG03548.1|ARO:3003681|TriC	25.3	510	517	1015	1.30e-46	173
k141_76806_1	SARG|CAY51926	28.3	300	517	1008	3.31e-21	96.7
k141_76806_1	SARG|YP_350221	28.6	301	517	1009	7.75e-21	95.5
k141_76806_1	SARG|YP_001670703	28.4	303	517	1014	2.31e-19	90.9
k141_76806_1	SARG|YP_001266290	28.4	303	517	1014	5.38e-19	89.7
k141_76806_1	SARG|YP_001186705	27.8	302	517	1017	1.66e-18	88.2
k141_76806_1	SARG|YP_792720	27.3	311	517	1018	3.86e-18	87.0
k141_76806_1	SARG|AAG07763	27.3	311	517	1018	3.86e-18	87.0
k141_76806_1	SARG|YP_606823	27.9	298	517	1011	8.95e-18	85.9
k141_5836_1	CARD|gb|ADM92605.1|ARO:3000553|adeR	30.0	110	347	247	2.07e-06	47.4
k141_159481_3	SARG|gb|AAC75089.1|ARO:3003577|ugd	55.9	435	440	388	4.20e-162	461
k141_57477_1	ResF|tmexD3_1_LC633285_1	42.3	390	392	1044	1.63e-77	257
k141_57477_1	NCBI|WP_034065037.1|1|1|tmexD3|tmexD|efflux|2|TIGECYCLINE|TETRACYCLINE|multidrug_efflux_RND_transporter_permease_subunit_TMexD3|AMR|tetracycline	42.1	390	392	1044	3.11e-77	256
k141_57477_1	NCBI|WP_118842627.1|1|1|tmexD1|tmexD|efflux|2|TIGECYCLINE|TETRACYCLINE|multidrug_efflux_RND_transporter_permease_subunit_TMexD1|AMR|tetracycline	41.9	389	392	1044	5.93e-77	256
k141_57477_1	SARG|gi|852273548|ref|WP_048328542.1|	42.6	385	392	1043	8.11e-77	255
k141_57477_1	ResF|tmexD4_1_CP091084_1	41.9	389	392	1044	1.13e-76	255
k141_57477_1	NCBI|WP_027591160.1|1|1|tmexD2|tmexD|efflux|2|TIGECYCLINE|TETRACYCLINE|multidrug_efflux_RND_transporter_permease_subunit_TMexD2|AMR|tetracycline	41.6	389	392	1044	4.09e-76	253
k141_57477_1	SARG|YP_348488	41.0	388	392	1043	5.02e-74	248
k141_57477_1	SARG|YP_001668663	42.7	386	392	1043	6.91e-74	247
k141_57477_1	SARG|CAG34257	40.2	391	392	1040	2.43e-73	246
k141_57477_1	SARG|gi|499256187|ref|WP_010953727.1|	40.9	389	392	1042	2.47e-73	246
k141_25604_1	SARG|gb|BAG33043.1|ARO:3003920|pgpB	43.4	99	119	236	1.48e-20	82.0
k141_25604_1	megares|MEG_5776|Drugs|Lipopeptide|Lipid_A_phosphatase|PGBB_1	43.4	99	119	236	1.48e-20	82.0
k141_98388_1	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.5	121	602	219	1.32e-18	84.0
k141_98388_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.0	126	602	228	1.27e-15	75.5
k141_98388_1	CARD|gb|AAG06465.1|ARO:3005063|cprR	39.0	118	602	223	5.29e-15	73.6
k141_98388_1	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.0	128	602	220	1.24e-14	72.4
k141_98388_1	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.7	123	602	219	2.24e-14	71.6
k141_98388_1	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.7	123	602	219	2.24e-14	71.6
k141_98388_1	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.7	123	602	220	2.28e-14	71.6
k141_98388_1	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.3	122	602	220	3.09e-14	71.2
k141_98388_1	SARG|ZP_02848503	28.7	122	602	221	2.41e-11	62.8
k141_129536_1	CARD|gb|AAL14439.1|ARO:3000774|adeA	31.3	160	268	396	5.45e-10	58.2
k141_37252_1	CARD|gb|AAC75429.1|ARO:3000833|evgS	28.3	374	669	1197	1.67e-30	127
k141_37252_1	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	29.1	251	669	386	3.56e-21	95.1
k141_37252_1	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	29.1	251	669	386	3.56e-21	95.1
k141_37252_1	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.3	251	669	382	8.21e-21	94.0
k141_37252_1	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	28.3	251	669	382	8.21e-21	94.0
k141_37252_1	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	27.9	251	669	384	3.64e-20	92.0
k141_37252_1	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	27.9	251	669	384	3.64e-20	92.0
k141_37252_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.5	253	669	370	5.61e-20	91.3
k141_37252_1	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	25.9	247	669	365	4.15e-19	88.6
k141_37252_1	CARD|gb|CYF42523.1|ARO:3004047|kdpD	24.1	228	669	885	3.07e-15	78.6
k141_47523_3	CARD|gb|AAC75137.1|ARO:3000794|mdtC	29.5	701	713	1025	1.92e-75	261
k141_47523_3	SARG|gb|AAG05914|ARO:3004075|MuxC	28.5	706	713	1036	1.61e-63	228
k141_47523_3	SARG|YP_350221	27.0	700	713	1009	1.85e-63	227
k141_47523_3	SARG|YP_792720	26.9	700	713	1018	6.67e-63	226
k141_47523_3	SARG|YP_001350280	26.9	700	713	1018	1.23e-62	225
k141_47523_3	SARG|AAG07763	26.7	700	713	1018	2.27e-62	224
k141_47523_3	SARG|YP_001186705	26.7	704	713	1017	4.15e-62	223
k141_47523_3	SARG|YP_001266290	27.1	700	713	1014	3.45e-61	221
k141_47523_3	CARD|gb|AAG07594.1|ARO:3000808|MexI	27.8	699	713	1029	5.08e-61	220
k141_47523_3	NCBI|AAN33534.1|1|1|bepG|bepG|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepG|AMR|efflux	26.3	700	713	1074	8.47e-61	220
k141_88453_1	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	24.8	290	252	346	1.40e-08	53.5
k141_25911_2	CARD|gb|ADM92605.1|ARO:3000553|adeR	30.8	143	252	247	1.37e-07	50.1
k141_77725_2	NCBI|AAN33534.1|1|1|bepG|bepG|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepG|AMR|efflux	49.1	230	234	1074	7.72e-61	204
k141_77725_2	SARG|gi|966476691|ref|WP_058507424.1|	46.5	228	234	1063	8.74e-52	179
k141_77725_2	SARG|gi|966506160|ref|WP_058522806.1|	46.4	224	234	1066	8.75e-52	179
k141_77725_2	SARG|gb|BAE06008.1|ARO:3003699|mexQ	45.5	220	234	1053	1.61e-51	178
k141_77725_2	SARG|gi|966439914|ref|WP_058480237.1|	45.7	223	234	1054	2.20e-51	177
k141_77725_2	SARG|gi|966511896|ref|WP_058528450.1|	45.5	224	234	1061	2.21e-51	177
k141_77725_2	SARG|gi|852273548|ref|WP_048328542.1|	47.4	213	234	1043	2.97e-51	177
k141_77725_2	SARG|gi|966461601|ref|WP_058493954.1|	44.7	226	234	1054	3.00e-51	177
k141_77725_2	SARG|gi|966407319|ref|WP_058450725.1|	44.9	227	234	1062	3.01e-51	177
k141_77725_2	SARG|U57969.gene.p01	47.4	213	234	1043	4.05e-51	177
k141_140428_1	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	37.5	200	190	1186	1.27e-29	113
k141_140428_1	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	37.5	200	190	1186	1.27e-29	113
k141_140428_1	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	34.2	184	190	1162	1.32e-25	102
k141_109479_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	33.2	217	228	228	7.65e-32	115
k141_109479_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.3	208	228	231	1.46e-28	106
k141_109479_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	28.8	222	228	219	1.02e-24	96.3
k141_109479_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	28.0	211	228	232	1.41e-23	93.6
k141_109479_2	CARD|gb|AAG05188.1|ARO:3005068|ParR	27.5	222	228	235	5.92e-22	89.4
k141_109479_2	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	27.8	223	228	231	5.82e-18	78.6
k141_109479_2	CARD|gb|ADM92605.1|ARO:3000553|adeR	35.1	111	228	247	5.32e-17	76.3
k141_109479_2	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	25.8	225	228	233	2.20e-16	74.3
k141_109479_2	CARD|gb|AAC75429.1|ARO:3000833|evgS	40.2	102	228	1197	1.39e-15	74.3
k141_109479_2	CARD|gb|BAB36671.1|ARO:3000832|evgA	22.5	111	228	204	3.54e-07	48.1
k141_99206_1	SARG|gi|654923461|ref|WP_028373991.1|	20.9	511	484	1069	6.67e-16	79.7
k141_48490_1	SARG|gb|BAA11237.1|ARO:3000254|emrY	27.6	127	362	512	7.96e-07	49.7
k141_89587_1	SARG|gb|AQX82857.1|ARO:3004185|mecD	26.1	425	418	678	3.73e-24	103
k141_89587_1	SARG|AAX35723	25.0	424	418	665	7.13e-22	97.1
k141_89587_1	SARG|gi|2791908|emb|CAA73538.1|	24.8	424	418	666	7.14e-22	97.1
k141_89587_1	megares|MEG_3792|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	24.9	425	418	666	7.14e-22	97.1
k141_89587_1	SARG|CAA70425	24.8	424	418	666	9.56e-22	96.7
k141_89587_1	megares|MEG_3790|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	24.5	424	418	666	1.28e-21	96.3
k141_89587_1	megares|MEG_3800|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	23.3	424	418	665	3.06e-21	95.1
k141_89587_1	NCBI|WP_063852700.1|1|1|mecA2|mecA2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA2|AMR|beta-lactam	23.7	426	418	668	3.08e-21	95.1
k141_89587_1	NCBI|WP_063852694.1|1|1|mecA2|mecA2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA2|AMR|beta-lactam	23.7	426	418	668	4.11e-21	94.7
k141_89587_1	megares|MEG_3799|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	25.3	332	418	664	5.48e-21	94.4
k141_26833_1	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.4	143	304	231	1.35e-21	90.1
k141_26833_1	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.4	143	304	231	1.87e-21	89.7
k141_26833_1	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.4	143	304	231	2.59e-21	89.4
k141_26833_1	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	36.0	125	304	230	2.39e-19	84.0
k141_26833_1	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	34.4	125	304	229	8.55e-19	82.4
k141_26833_1	CARD|gb|ATC67679.1|ARO:3000838|arlR	32.8	119	304	219	3.64e-14	69.3
k141_26833_1	CARD|gb|AAD51348.1|ARO:3003066|smeR	26.7	120	304	229	1.30e-12	65.1
k141_26833_1	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	25.7	214	304	220	7.32e-10	57.0
k141_26833_1	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	25.7	214	304	219	9.81e-10	56.6
k141_26833_1	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	25.7	214	304	219	1.33e-09	56.2
k141_99656_2	CARD|gb|ABD30512.1|ARO:3000839|arlS	25.7	230	314	451	1.62e-12	66.6
k141_26948_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	34.7	118	128	231	4.50e-15	67.8
k141_26948_1	CARD|gb|ADM92605.1|ARO:3000553|adeR	32.5	114	128	247	1.06e-14	67.0
k141_26948_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	34.8	115	128	232	1.23e-14	66.6
k141_26948_1	CARD|gb|AAC75429.1|ARO:3000833|evgS	34.6	107	128	1197	3.89e-14	66.6
k141_26948_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.7	114	128	228	1.19e-12	61.2
k141_161117_1	CARD|gb|AAC75136.1|ARO:3000793|mdtB	43.1	65	106	1040	2.16e-08	49.3
k141_59182_1	SARG|FN594949.1.gene24.p01	38.9	193	261	640	1.75e-37	138
k141_59182_1	NCBI|WP_003454408.1|1|1|tet(44)|tet(44)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(44)|AMR|tetracycline	41.9	172	261	640	2.40e-37	137
k141_59182_1	SARG|NP_348076	36.9	217	261	652	1.70e-36	135
k141_59182_1	SARG|YP_002850805	45.2	146	261	652	4.36e-36	134
k141_59182_1	SARG|CAA37477	35.2	250	261	663	4.57e-36	134
k141_59182_1	SARG|L42544.gene.p01	46.6	148	261	651	5.95e-36	134
k141_59182_1	SARG|AAV80410	46.6	148	261	651	5.95e-36	134
k141_59182_1	SARG|ZP_02952732	45.2	146	261	652	1.53e-35	132
k141_59182_1	SARG|L20800.gene.p01	45.2	146	261	652	1.53e-35	132
k141_59182_1	SARG|ZP_02632674	45.2	146	261	660	1.59e-35	132
k141_27283_1	CARD|gb|AAC75429.1|ARO:3000833|evgS	29.9	344	408	1197	2.06e-31	125
k141_27283_1	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	42.3	104	408	239	2.28e-18	82.8
k141_27283_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.7	103	408	232	2.74e-18	82.4
k141_27283_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.7	103	408	232	2.74e-18	82.4
k141_27283_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.5	104	408	232	1.77e-17	80.1
k141_27283_1	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	40.7	108	408	230	3.16e-17	79.3
k141_27283_1	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.0	117	408	219	8.95e-17	77.8
k141_27283_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.6	104	408	231	2.05e-16	77.0
k141_27283_1	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	36.5	104	408	232	1.79e-15	74.3
k141_27283_1	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	36.5	104	408	232	1.79e-15	74.3
k141_27351_3	SARG|gi|489931383|ref|WP_003834702.1|	34.2	152	231	660	6.15e-24	98.6
k141_27351_3	SARG|gi|696369048|ref|WP_032944060.1|	34.2	152	231	660	8.35e-24	98.2
k141_27351_3	SARG|gi|851935911|ref|WP_048224705.1|	34.9	152	231	660	2.84e-23	96.7
k141_27351_3	SARG|gi|851912779|ref|WP_048215868.1|	34.2	152	231	660	2.84e-23	96.7
k141_27351_3	SARG|YP_002850217	32.9	152	231	660	3.85e-23	96.3
k141_27351_3	SARG|gi|851965596|ref|WP_048234849.1|	32.9	152	231	660	3.85e-23	96.3
k141_27351_3	SARG|gi|851899656|ref|WP_048211088.1|	32.9	152	231	660	3.85e-23	96.3
k141_27351_3	SARG|gi|1002399350|ref|WP_061382108.1|	34.9	152	231	660	3.85e-23	96.3
k141_27351_3	SARG|gi|757799830|ref|WP_043017032.1|	34.2	152	231	660	3.85e-23	96.3
k141_27351_3	SARG|gi|489117806|ref|WP_003027650.1|	34.2	152	231	660	3.85e-23	96.3
k141_27386_2	SARG|YP_001401993	56.7	215	216	404	1.54e-79	242
k141_27386_2	SARG|AAC60781	56.0	216	216	410	3.63e-79	241
k141_27386_2	SARG|ZP_04623896	54.6	216	216	380	6.23e-79	240
k141_27386_2	SARG|YP_001477378	54.9	213	216	406	6.49e-79	241
k141_27386_2	SARG|YP_001605796	56.3	215	216	404	1.23e-78	240
k141_27386_2	SARG|YP_001871501	55.8	215	216	404	9.81e-78	238
k141_27386_2	SARG|ZP_04621517	53.7	216	216	404	3.13e-76	234
k141_27386_2	SARG|ZP_04612558	53.5	215	216	404	1.76e-75	232
k141_27386_2	SARG|ZP_04638972	53.5	215	216	404	1.76e-75	232
k141_27386_2	SARG|ZP_04631862	61.7	183	216	404	2.49e-75	231
k141_131690_2	SARG|gb|CAE00499.1|ARO:3003835|cdeA	30.0	350	366	441	3.13e-55	186
k141_161522_1	SARG|AAG08983	30.3	211	212	524	5.68e-27	106
k141_161522_1	NCBI|WP_032492560.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	34.6	185	212	522	2.72e-26	104
k141_161522_1	SARG|DQ823382.1.gene1.p01	34.6	185	212	522	2.72e-26	104
k141_161522_1	megares|MEG_7687|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	34.6	185	212	522	2.72e-26	104
k141_161522_1	megares|MEG_7686|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	34.6	185	212	522	2.72e-26	104
k141_161522_1	SARG|AAF24091	34.6	185	212	522	2.72e-26	104
k141_161522_1	SARG|YP_002332257	34.6	185	212	522	2.72e-26	104
k141_161522_1	SARG|KC539823.1.gene1.p01	34.1	185	212	522	5.09e-26	103
k141_161522_1	NCBI|WP_063856937.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	34.1	185	212	522	6.97e-26	103
k141_161522_1	SARG|FR772051.1.gene9.p01	30.3	201	212	524	2.19e-24	99.0
k141_49470_2	SARG|NP_348076	40.3	149	208	652	3.74e-25	101
k141_49470_2	SARG|YP_002850805	41.9	136	208	652	6.93e-25	100
k141_49470_2	SARG|ZP_02952732	40.9	149	208	652	6.93e-25	100
k141_49470_2	SARG|L20800.gene.p01	40.9	149	208	652	6.93e-25	100
k141_49470_2	SARG|ZP_02632674	40.9	149	208	660	6.96e-25	100
k141_49470_2	SARG|L42544.gene.p01	34.1	179	208	651	1.29e-22	94.0
k141_49470_2	SARG|AAV80410	34.1	179	208	651	1.29e-22	94.0
k141_49470_2	SARG|CAA37477	37.1	151	208	663	2.78e-21	90.1
k141_49470_2	SARG|ABN79417	40.3	134	208	639	1.27e-20	88.2
k141_49470_2	SARG|ABV82118	38.3	133	208	639	2.35e-20	87.4
k141_110602_5	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	27.3	542	735	574	6.08e-47	174
k141_110602_5	SARG|gb|AAC74000.1|ARO:3003950|msbA	26.6	545	735	582	1.73e-46	173
k141_110602_5	SARG|gi|926400371|ref|WP_053728483.1|	38.6	241	735	603	3.15e-46	173
k141_110602_5	SARG|gi|1045390184|ref|WP_065479071.1|	27.0	570	735	605	1.10e-45	171
k141_110602_5	SARG|gi|517347347|ref|WP_018522839.1|	27.5	578	735	601	1.42e-45	171
k141_110602_5	SARG|gi|497748188|ref|WP_010062372.1|	26.5	573	735	605	1.50e-45	171
k141_110602_5	SARG|gi|695865802|ref|WP_032778631.1|	26.7	573	735	605	1.50e-45	171
k141_110602_5	SARG|gi|516795764|ref|WP_018105258.1|	27.3	578	735	601	2.62e-45	170
k141_110602_5	SARG|gi|695842130|ref|WP_032755430.1|	26.9	561	735	603	3.66e-45	170
k141_110602_5	SARG|gi|764446018|ref|WP_044369325.1|	26.5	573	735	605	5.09e-45	169
k141_151188_1	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.4	163	678	365	2.47e-08	55.5
k141_151188_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.9	171	678	370	1.03e-07	53.5
k141_90411_1	SARG|CAY51926	25.9	487	507	1008	3.94e-31	127
k141_90411_1	SARG|YP_350221	25.3	459	507	1009	2.38e-28	118
k141_90411_1	SARG|gi|489273629|ref|WP_003181339.1|	24.6	468	507	1059	2.46e-23	103
k141_90411_1	SARG|gi|504104202|ref|WP_014338188.1|	24.4	468	507	1059	3.28e-23	102
k141_90411_1	SARG|gi|780147796|ref|WP_045491627.1|	24.9	462	507	1063	7.73e-23	101
k141_90411_1	SARG|gi|489294780|ref|WP_003202298.1|	24.4	468	507	1059	1.03e-22	101
k141_90411_1	SARG|gi|490552377|ref|WP_004417486.1|	24.8	467	507	1063	1.37e-22	100
k141_90411_1	SARG|YP_607927	25.8	461	507	1059	2.42e-22	100
k141_90411_1	SARG|gi|940417834|ref|WP_055007142.1|	24.6	467	507	1063	2.42e-22	100
k141_90411_1	SARG|gi|929531233|ref|WP_054071736.1|	24.8	467	507	1063	2.42e-22	100
k141_50001_1	SARG|YP_002861121	41.3	80	120	212	3.74e-15	67.4
k141_50001_1	SARG|YP_001779894	37.5	112	120	212	7.30e-15	66.6
k141_50001_1	SARG|YP_001389621	36.6	112	120	212	1.99e-14	65.5
k141_50001_1	SARG|U19459.gene.p01	31.1	119	120	212	2.78e-14	65.1
k141_50001_1	SARG|YP_001785579	36.6	112	120	212	3.88e-14	64.7
k141_50001_1	NCBI|WP_031281281.1|1|1|catB|catB|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B_phenicol_O-acetyltransferase|AMR|phenicol	37.5	80	120	210	5.27e-14	64.3
k141_50001_1	SARG|gb|AAF63432|ARO:3003744|vatF	35.0	100	120	221	6.20e-13	61.6
k141_50001_1	SARG|M58472.1.gene1.p01	46.4	56	120	209	1.04e-12	60.8
k141_50001_1	SARG|GQ205627.2.gene3.p01	32.7	113	120	216	1.58e-12	60.5
k141_50001_1	SARG|ABD04054	32.7	107	120	210	3.96e-12	59.3
k141_50061_2	SARG|P42332	33.6	214	251	306	2.66e-33	121
k141_50061_2	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	33.6	214	251	306	2.66e-33	121
k141_50061_2	SARG|gi|510143239|gb|AGN36970.1|	33.6	214	251	313	3.06e-33	121
k141_50061_2	SARG|ABB80128	33.6	214	251	306	5.20e-33	120
k141_50061_2	SARG|AAD21213	33.6	214	251	306	1.02e-32	120
k141_121613_1	SARG|AAA67509	37.1	89	113	538	7.53e-14	65.1
k141_121613_1	SARG|YP_002193132	33.3	99	113	537	1.03e-13	64.7
k141_121613_1	SARG|YP_002181880	31.0	113	113	536	2.61e-13	63.5
k141_121613_1	SARG|NP_826974	34.1	88	113	540	2.61e-13	63.5
k141_121613_1	SARG|NP_733568	33.3	117	113	536	4.86e-13	62.8
k141_121613_1	SARG|YP_002188856	32.2	118	113	537	6.64e-13	62.4
k141_121613_1	SARG|YP_002196817	31.4	102	113	536	9.05e-13	62.0
k141_121613_1	SARG|YP_002203876	33.0	88	113	539	1.09e-11	58.9
k141_121613_1	SARG|gi|828164785|ref|WP_047255785.1|	36.8	87	113	513	1.48e-11	58.5
k141_121613_1	SARG|gi|928870254|ref|WP_053909077.1|	36.8	87	113	513	1.48e-11	58.5
k141_121613_2	CARD|gb|AAK37618.1|ARO:3005008|TxR	40.5	299	450	318	2.82e-63	206
k141_162281_3	CARD|gb|AAC75429.1|ARO:3000833|evgS	30.2	245	707	1197	4.95e-26	113
k141_121826_1	SARG|gb|AAC74000.1|ARO:3003950|msbA	43.2	373	370	582	3.55e-81	258
k141_121826_1	SARG|gi|664579989|ref|WP_031094015.1|	42.5	320	370	601	4.55e-79	253
k141_121826_1	SARG|gi|928900436|ref|WP_053931243.1|	42.9	315	370	600	8.78e-79	252
k141_121826_1	SARG|gi|664556405|ref|WP_031071225.1|	42.5	315	370	602	1.95e-77	248
k141_121826_1	SARG|gi|944470764|ref|WP_055701183.1|	42.9	315	370	601	5.64e-76	244
k141_121826_1	SARG|gi|1011969930|ref|WP_062776015.1|	41.9	315	370	601	7.92e-76	244
k141_121826_1	SARG|gi|664244930|ref|WP_030776974.1|	41.6	315	370	601	2.19e-75	243
k141_121826_1	SARG|gi|655401130|ref|WP_028800283.1|	42.2	315	370	599	4.12e-75	242
k141_121826_1	SARG|gi|943909899|ref|WP_055545300.1|	41.6	315	370	601	8.47e-75	241
k141_121826_1	SARG|gi|817122037|ref|WP_046494699.1|	41.1	321	370	613	1.53e-74	241
k141_152055_2	CARD|gb|ADM92605.1|ARO:3000553|adeR	35.6	104	132	247	3.17e-13	63.2
k141_152055_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	32.4	102	132	229	1.34e-11	58.5
k141_152055_2	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	29.5	105	132	225	1.58e-08	50.1
k141_152055_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.2	106	132	219	3.67e-07	46.2
k141_152055_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.2	76	132	228	3.84e-07	46.2
k141_101248_2	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	68.0	219	230	443	1.13e-100	298
k141_9344_1	SARG|gb|CAE00499.1|ARO:3003835|cdeA	25.3	178	204	441	3.44e-11	60.5
k141_9394_1	SARG|gi|749639729|ref|WP_040241690.1|	37.3	169	169	646	1.48e-36	132
k141_162825_1	SARG|YP_002850805	26.5	393	397	652	1.23e-34	134
k141_162825_1	SARG|NP_348076	25.2	397	397	652	4.21e-34	132
k141_162825_1	SARG|AAV80410	27.1	395	397	651	1.43e-33	131
k141_162825_1	SARG|ZP_02952732	25.4	394	397	652	2.64e-33	130
k141_162825_1	SARG|L20800.gene.p01	25.4	394	397	652	2.64e-33	130
k141_162825_1	SARG|ZP_02632674	25.4	394	397	660	2.73e-33	130
k141_162825_1	SARG|L42544.gene.p01	27.1	395	397	651	4.85e-33	129
k141_162825_1	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.8	396	397	641	1.58e-32	128
k141_162825_1	SARG|AAZ79478	26.8	396	397	657	1.68e-32	128
k141_162825_1	SARG|Q08425	25.7	393	397	641	7.26e-32	126
k141_101731_3	CARD|gb|AEX49906.1|ARO:3003583|basS	25.1	247	391	477	3.36e-12	66.6
k141_101754_2	SARG|gi|671541568|ref|WP_031525212.1|	33.8	77	297	648	5.59e-07	49.7
k141_143332_2	SARG|gb|ADZ12700.1|ARO:3005090|RanB	54.4	149	148	253	9.99e-43	140
k141_28961_3	SARG|NP_348076	58.1	31	57	652	6.16e-06	40.0
k141_61609_2	SARG|gb|AAF40763.1|ARO:3003961|farA	51.1	45	56	384	1.49e-08	47.4
k141_61609_2	SARG|gi|510927038|ref|WP_016247755.1|	51.1	47	56	390	1.49e-08	47.4
k141_61609_2	SARG|gb|BAA16547.1|ARO:3000027|emrA	52.2	46	56	390	2.04e-08	47.0
k141_61609_2	SARG|gi|692990270|ref|WP_032178668.1|	52.2	46	56	390	2.04e-08	47.0
k141_61609_2	SARG|gi|765410328|ref|WP_044688844.1|	52.2	46	56	390	2.04e-08	47.0
k141_61609_2	SARG|gi|763189942|ref|WP_044067173.1|	52.2	46	56	390	2.04e-08	47.0
k141_61609_2	SARG|gi|485788756|ref|WP_001410907.1|	52.2	46	56	390	2.04e-08	47.0
k141_61609_2	SARG|gi|545301157|ref|WP_021580954.1|	52.2	46	56	390	2.04e-08	47.0
k141_61609_2	SARG|gi|553952462|ref|WP_023150966.1|	52.2	46	56	390	2.04e-08	47.0
k141_61609_2	SARG|NC_002695.1.914737.p01	52.2	46	56	390	2.04e-08	47.0
k141_123020_1	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	24.5	245	410	443	1.50e-13	70.9
k141_92234_1	SARG|gi|739062736|ref|WP_036934147.1|	22.6	217	311	463	2.27e-06	47.8
k141_92234_1	SARG|gi|559234117|ref|WP_023582764.1|	22.8	219	311	465	4.03e-06	47.0
k141_92234_1	SARG|gi|225204373|gb|EEG86727.1|	22.8	219	311	366	4.66e-06	46.6
k141_92234_1	SARG|gi|857585365|emb|CRL63509.1|	22.8	219	311	465	5.36e-06	46.6
k141_80564_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	37.5	104	320	231	1.20e-15	73.9
k141_80564_2	CARD|gb|AAG06465.1|ARO:3005063|cprR	31.1	122	320	223	8.46e-10	57.0
k141_102130_3	SARG|gi|542061059|gb|ERI11611.1|	30.7	179	178	316	2.06e-20	85.1
k141_102130_3	SARG|gi|500448961|gb|EOP61695.1|	31.8	179	178	306	1.81e-19	82.4
k141_102130_3	SARG|gi|500465078|gb|EOP76697.1|	31.8	179	178	306	3.48e-19	81.6
k141_102130_3	SARG|gi|446026113|ref|WP_000103968.1|	31.8	176	178	306	4.83e-19	81.3
k141_102130_3	SARG|gi|507044560|ref|WP_016115614.1|	31.8	176	178	306	9.26e-19	80.5
k141_102130_3	SARG|gi|500194536|ref|WP_011867743.1|	31.8	176	178	306	2.46e-18	79.3
k141_102130_3	SARG|gi|445996710|ref|WP_000074565.1|	30.7	179	178	309	2.53e-18	79.3
k141_102130_3	SARG|YP_001373621	30.2	179	178	318	3.82e-18	79.0
k141_102130_3	SARG|gi|507055561|ref|WP_016126482.1|	30.7	179	178	309	4.84e-18	78.6
k141_102130_3	SARG|gi|445996709|ref|WP_000074564.1|	30.2	179	178	309	6.70e-18	78.2
k141_71208_3	SARG|EU408352.1.gene1.p01	34.4	215	269	469	2.55e-30	117
k141_71208_3	SARG|gi|573999612|gb|ETU76469.1|	28.1	224	269	366	1.20e-24	100
k141_71208_3	SARG|gi|553749675|ref|WP_023082630.1|	28.6	224	269	485	3.18e-24	100
k141_71208_3	SARG|gi|872500954|emb|CRR52030.1|	28.1	224	269	440	6.23e-24	99.0
k141_71208_3	SARG|gi|553757603|ref|WP_023090259.1|	28.1	224	269	485	8.08e-24	99.0
k141_71208_3	SARG|NC_002516.2.877851.p01	28.1	224	269	485	8.08e-24	99.0
k141_71208_3	SARG|YP_001345922	28.1	224	269	485	8.08e-24	99.0
k141_71208_3	SARG|YP_002083353	27.7	224	269	485	2.05e-23	97.8
k141_71208_3	SARG|gi|872543126|emb|CRW86548.1|	26.4	208	269	420	3.03e-19	85.5
k141_71208_3	SARG|gi|872412160|emb|CRX31464.1|	26.4	208	269	420	3.03e-19	85.5
k141_80893_1	SARG|gb|APB03218.1|ARO:3003984|BahA	38.1	527	528	752	7.04e-100	317
k141_80893_1	megares|MEG_1196|Drugs|Bacitracin|Undecaprenyl_pyrophosphate_phosphatase|BAHA_1	38.1	527	528	752	7.04e-100	317
k141_29581_2	NCBI|AAN29241.1|1|1|bepE|bepE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepE|AMR|efflux	31.4	159	216	1051	6.89e-19	83.6
k141_29581_2	CARD|gb|AAC75136.1|ARO:3000793|mdtB	34.8	138	216	1040	9.34e-19	83.2
k141_29581_2	CARD|gb|AAL14440.1|ARO:3000775|adeB	25.8	182	216	1035	1.07e-17	80.1
k141_29581_2	SARG|gb|AAG05915.1|ARO:3004074|MuxB	31.9	138	216	1043	1.66e-16	76.6
k141_29581_2	SARG|gb|AAG05914|ARO:3004075|MuxC	32.3	130	216	1036	3.25e-13	67.0
k141_153214_3	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	49.1	230	259	443	2.50e-67	214
k141_71768_1	NCBI|WP_063865368.1|1|1|oqxA4|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA4|AMR|multidrug	28.7	314	361	391	2.55e-35	132
k141_71768_1	NCBI|WP_063865358.1|1|1|oqxA2|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA2|AMR|multidrug	28.7	314	361	391	1.31e-34	130
k141_71768_1	NCBI|WP_047693838.1|1|1|oqxA6|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA6|AMR|multidrug	28.3	314	361	391	1.31e-34	130
k141_71768_1	NCBI|WP_004890321.1|1|1|oqxA3|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA3|AMR|multidrug	28.3	314	361	391	1.31e-34	130
k141_71768_1	SARG|gb|AAP43109.1|ARO:3003922|oqxA	28.3	314	361	391	1.81e-34	129
k141_71768_1	NCBI|WP_004212918.1|1|1|oqxA11|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA11|AMR|multidrug	28.3	314	361	391	1.81e-34	129
k141_71768_1	NCBI|WP_063865390.1|1|1|oqxA8|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA8|AMR|multidrug	28.3	314	361	391	1.81e-34	129
k141_71768_1	NCBI|WP_004149398.1|1|1|oqxA10|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA10|AMR|multidrug	28.3	314	361	391	3.48e-34	129
k141_71768_1	NCBI|WP_063865399.1|1|1|oqxA9|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA9|AMR|multidrug	28.0	314	361	391	4.82e-34	128
k141_71768_1	NCBI|WP_063865373.1|1|1|oqxA5|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA5|AMR|multidrug	28.0	314	361	391	6.68e-34	128
k141_19500_1	NCBI|CBE03766.1|1|1|nimB-Cd|nimB-Cd||1|NITROIMIDAZOLE|NITROIMIDAZOLE|putative_5-nitroimidazole_reductase_NimB-Cd|AMR|nitroimidazole	44.0	84	84	155	1.23e-20	79.0
k141_20407_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	34.2	117	122	229	7.18e-14	64.3
k141_20407_2	CARD|gb|ADM92605.1|ARO:3000553|adeR	30.8	120	122	247	8.75e-14	64.3
k141_20407_2	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	29.2	120	122	239	1.51e-11	58.2
k141_20407_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	28.8	118	122	219	6.30e-10	53.5
k141_20407_2	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	31.2	77	122	233	7.84e-07	45.1
k141_20407_2	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	29.9	77	122	231	3.75e-06	43.1
